Cargando…

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial

Aim: To verify the superiority of pemafibrate over placebo and the non-inferiority of pemafibrate to the maximum dose of fenofibrate for determining the percent change in fasting serum triglyceride (TG) levels and to investigate safety by assessing the incidence of adverse events (AEs) and adverse d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arai, Hidenori, Yamashita, Shizuya, Yokote, Koutaro, Araki, Eiichi, Suganami, Hideki, Ishibashi, Shun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005227/ https://www.ncbi.nlm.nih.gov/pubmed/29628483 http://dx.doi.org/10.5551/jat.44412

Ejemplares similares

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
por: Yokote, Koutaro, et al.
Publicado: (2019)

Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials
por: Yokote, Koutaro, et al.
Publicado: (2021)

Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
por: Matsuba, Ikuro, et al.
Publicado: (2018)

Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study
por: Araki, Eiichi, et al.
Publicado: (2019)

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate
por: Yamashita, Shizuya, et al.
Publicado: (2021)

Association between Pemafibrate Therapy and Triglyceride to HDL-Cholesterol Ratio
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Event Monitoring and Evaluation by Community Pharmacists in Japan: A Pilot Study on Fenofibrate and Pemafibrate
por: Takahashi, Masao, et al.
Publicado: (2022)

Endothelial Function in Dyslipidemia: Roles of LDL-Cholesterol, HDL-Cholesterol and Triglycerides
por: Higashi, Yukihito
Publicado: (2023)

Triglycerides and HDL Cholesterol: Stars or second leads in diabetes?
por: Bitzur, Rafael, et al.
Publicado: (2009)

WWOX gene is associated with HDL cholesterol and triglyceride levels
por: Sáez, María E, et al.
Publicado: (2010)

Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017
por: Harada-Shiba, Mariko, et al.
Publicado: (2018)

Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Serum HDL-Cholesterol Level Does Not Influence Cardiovascular Event Rate under Sufficient Lowering of LDL-Cholesterol by Pitavatatin in Patients with Stable Coronary Artery Disease
por: Masuda, Daisaku, et al.
Publicado: (2022)

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

Erratum:A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

Low HDL Cholesterol Is Associated With the Risk of Stroke in Elderly Diabetic Individuals: Changes in the risk for atherosclerotic diseases at various ages
por: Hayashi, Toshio, et al.
Publicado: (2009)

Calculated Non-HDL Cholesterol Includes Cholesterol in Larger Triglyceride-Rich Lipoproteins in Hypertriglyceridemia
por: Sun, Cathy J, et al.
Publicado: (2019)

Triglyceride Level and Cardiovascular Risk Reduction Using Pemafibrate Compared with Fibrates
por: Masuda, Daisaku
Publicado: (2023)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

High Ratio of Triglycerides to HDL-Cholesterol Predicts Extensive Coronary Disease
por: da Luz, Protasio Lemos, et al.
Publicado: (2008)

Differences in the Triglyceride to HDL-Cholesterol Ratio between Palestinian and Israeli Adults
por: Weiss, Ram, et al.
Publicado: (2015)

Triglyceride/HDL-Cholesterol Ratio as an Index of Intracranial Atherosclerosis in Nonstroke Individuals
por: Woo, Min-Hee, et al.
Publicado: (2021)

Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate
por: Honda, Akihiro, et al.
Publicado: (2022)

Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion
por: Kitamura, Shigeki, et al.
Publicado: (2023)

Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report
por: Iitake, Chie, et al.
Publicado: (2020)

Detection of quantitative trait loci affecting serum cholesterol, LDL, HDL, and triglyceride in pigs
por: Uddin, Muhammad Jasim, et al.
Publicado: (2011)

Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: Real-world results and factors associated with triglyceride reduction
por: Woo, Yeongmin, et al.
Publicado: (2018)

A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients
por: Yanai, Hidekatsu, et al.
Publicado: (2021)

Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

The PPAR Alpha gene is associated with triglyceride, low-density cholesterol, and inflammation marker response to fenofibrate intervention: The GOLDN Study
por: Frazier-Wood, A.C., et al.
Publicado: (2012)

Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial
por: Tsujita, Kenichi, et al.
Publicado: (2023)

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
por: Nakajima, Atsushi, et al.
Publicado: (2021)

The Triglyceride-to-HDL Cholesterol Ratio: Association with insulin resistance in obese youths of different ethnic backgrounds
por: Giannini, Cosimo, et al.
Publicado: (2011)

High triglyceride/HDL cholesterol ratio is associated with silent brain infarcts in a healthy population
por: Nam, Ki-Woong, et al.
Publicado: (2019)

Triglycerides and low HDL cholesterol predict coronary heart disease risk in patients with stable angina
por: Caselli, Chiara, et al.
Publicado: (2021)

The Potential of ANGPTL8 Antagonism to Simultaneously Reduce Triglyceride and Increase HDL-Cholesterol Plasma Levels
por: Zhang, Ren
Publicado: (2021)

Triglycerides/HDL cholesterol ratio and type 2 diabetes incidence: Panasonic Cohort Study 10
por: Yuge, Hiroki, et al.
Publicado: (2023)

ABO gene polymorphisms are associated with acute coronary syndrome and with plasma concentration of HDL-cholesterol and triglycerides
por: Vargas-Alarcón, Gilberto, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pa5q6biafoqrfm0qkbgoqa5kta